Literature DB >> 30713327

Osteomalacia and Fanconi Syndrome Induced by Adefovir.

Natsumi Matsuoka1,2, Haruhito A Uchida1,3, Yoshikazu Hara2, Hiroto Matsuda2.   

Abstract

Entities:  

Keywords:  Fanconi syndrome; adefovir; chronic hepatitis B; osteomalacia

Year:  2019        PMID: 30713327      PMCID: PMC6599915          DOI: 10.2169/internalmedicine.2229-18

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


× No keyword cloud information.
A 77-year-old man with a history of taking adefovir at 10 mg/day for 10 years for chronic hepatitis B was referred due to multiple fractures without any trauma. He had mild renal dysfunction (sCr 1.28 mg/dL), hypophosphatemia (iP 1.9 mg/dL), hypouricemia (UA 1.4 mg/dL), phosphaturia, glycosuria without hyperglycemia, non-anion-gap metabolic acidosis, a normal range of vitamin D and intact parathormone, and a high concentration of ALP (922 IU/L), indicating a diagnosis of Fanconi syndrome. A renal biopsy revealed interstitial nephritis and intact glomeruli, compatible with the diagnosis. Bone scintigraphy showed an uptake at multiple points, including the costochondral junction, sternum and pseudofractures, demonstrating osteomalacia caused by Fanconi syndrome (Picture). After switching from adefovir to entecavir and starting alfacalcidol and phosphates, the patient’s incident pain and laboratory findings dramatically improved. Regular monitoring of the renal function, including serum uric acid, serum phosphate, and urinalysis findings, is recommended to avoid Fanconi syndrome associated with the prolonged use of adefovir (1).
Picture.
The authors state that they have no Conflict of Interest (COI).
  1 in total

Review 1.  Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B.

Authors:  Hiroyuki Eguchi; Munehisa Tsuruta; Junichi Tani; Reiichiro Kuwahara; Yuji Hiromatsu
Journal:  Intern Med       Date:  2014       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.